Table of Contents
Share At:
Listen Article:
0:00 /
0:00
Bevacizumab Injection for Treating Different Ailments
Table of Contents
Several factors must be considered when planning the administration of Bevacizumab Injection. These include the dosage, safety and precautions. In addition, patients must be informed of the benefits of the drug.
What is the Dosage of Bevacizumab Injection?
Several types of Bevacizumab injection products are available to treat hepatocellular carcinoma. They are typically given once every two or three weeks. The dose will vary depending on the body’s response.
Bevacizumab is a medication that stops cancer from growing blood vessels. It binds to the protein VEGF, which is involved in blood vessel growth in many types of cancer.
Is Bevacizumab Injection Safe to Use?
Among the anti-angiogenic agents, bevacizumab injection is a potent inhibitor of microvascular permeability, vascularisation of tumours and growth of new tumour vasculature. Its activity is based on its ability to inhibit the binding of vascular endothelial growth factor (VEGF) to receptors. Bevacizumab is approved for the treatment of unresectable advanced metastatic non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC) and metastatic rectum cancer (MRCC) in adult patients. In combination with chemotherapy, bevacizumab significantly improved progression-free survival.
The US Food and Drug Administration (FDA) has approved Bevacizumab as a treatment for choroidal neovascularization (CNV). Bevacizumab is an inhibitor of vascular endothelial growth factor-A (VEGF-A), a protein that promotes neovascularization of the eye. It is thought to be a safer alternative to thermal laser therapy.
Macular Edema Treatment with Bevacizumab
Previously, the use of anti-VEGF agents for the treatment of macular edema in patients with central retinal vein occlusion (CRVO) has been investigated. In the Ranibizumab for Macular Edema after Central Retinal Vein OcclUsIon (RETAIN) study, patients with macular edema secondary to CRVO were treated with ranibizumab.
Compared with patients with central retinal vein occlusion who received ranibizumab, patients with macular edema in the iCRVO group who received bevacizumab had a reduction in central choroidal thickness (CCT). The results showed that the CCT value was reduced from 730.1 mm to 260.3 mm at 25 weeks.
In Conclusion
Bevacizumab is a targeted therapy that targets the vascular endothelial growth factor (VEGF). VEGF is produced by the tumor and is responsible for forming new blood vessels. A targeted therapy is less likely to harm healthy cells than a chemotherapy drug.
